Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
- Conditions
- First Posted Date
- 2003-02-28
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT00055367
- Locations
- 🇺🇸
The Children's Hospital, Boston, Massachusetts, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
- First Posted Date
- 2002-11-05
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 90
- Registration Number
- NCT00048555
- Locations
- 🇺🇸
Research site, Charlottesville, Virginia, United States
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
- Conditions
- First Posted Date
- 2002-10-02
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 70
- Registration Number
- NCT00046488
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
- Conditions
- First Posted Date
- 2002-04-04
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT00032786
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
- Conditions
- First Posted Date
- 2002-04-04
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 905
- Registration Number
- NCT00032799
- Locations
- 🇺🇸
Elan Pharmaceuticals, San Diego, California, United States
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
- Conditions
- First Posted Date
- 2002-02-22
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT00031083
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2002-02-18
- Last Posted Date
- 2009-06-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1200
- Registration Number
- NCT00030966
- Locations
- 🇺🇸
Mercy Hospital Outpatient Pharmacy, Des Moines, Iowa, United States
🇺🇸University of Pittsburgh, Department of Neurology, Pittsburgh, Pennsylvania, United States
🇩🇪Asklepios Klinik Schildautal, Seesen/Harz, Germany
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2001-12-03
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 900
- Registration Number
- NCT00027300
- Locations
- 🇬🇧
Oldchurch Hospital, Essex, United Kingdom
🇧🇪National MS Centrum, Melsbroek, Belgium
🇺🇸University of Miami School of Medicine, Department of Neurology, Miami, Florida, United States